|Bid||30.00 x 800|
|Ask||36.70 x 1000|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||239.71|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
FRANKFURT/LONDON (Reuters) - Bayer has approached U.S. drug firm Elanco Animal Health to discuss a possible combination of their pet-health businesses to create an industry giant, three sources familiar with the matter told Reuters. The two companies are working with banks to ensure any merger would secure regulatory approval, the sources said, speaking on condition of anonymity. Bayer has delayed the launch of an auction to private equity funds to clinch a bilateral deal with Elanco, the fourth-largest player in the animal health industry globally, the sources said.
The size of Elanco Animal Health Incorporated (NYSE:ELAN), a US$12b large-cap, often attracts investors seeking a...
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and recouped their losses by the end of the first quarter. […]
A recent SEC filing reveals what led up to the sale of the Leawood animal health company to Elanco last year — and the misperception that Engaged Capital was an interested buyer.
Eli Lilly's (LLY) earnings beat estimates in Q1. Stock falls in pre-market trading as the company lowers its full-year revenue forecast.
Health care stocks were the best sector in the Standard & Poor's 500-stock index in 2018, according to Yardeni Research. The sector's 4.7% gain last year isn't exactly eye-popping. But consider that utilities (+0.5%) were the only sector in the black, and that the index itself lost 6.2% ... and you realize just how impressive health care actually was.As we look ahead to 2019, economic storm clouds appear to be gathering. Although a recession is unlikely in the year ahead, UCLA economists estimate that GDP growth will shrink from 3% in 2018 to 2% in 2019 and finally 1% in 2020.Thus, in the potential absence of a good offense, it makes sense for investors to buy some defense in 2019. The best health care stocks can fit that bill. "Health care is a defensive growth sector that we think should have a growth upturn over the next five years or so," Saira Malik, head of global equities at Nuveen, told Fortune in November.With that in mind, here are 10 health care stocks to buy for 2019. SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond
Elanco Animal Health Inc (NYSE: ELAN) announced Friday that it has struck a deal to buy pet therapeutics company Aratana Therapeutics Inc (NASDAQ: PETX). The stock-for-stock deal is worth as much as $245 million, Elanco said. The deal would grant Aratana shareholders 0.1481 Elanco shares and one cash contingent value right for each Aratana share, and the shares to be issued represent about 2 percent of outstanding Elanco shares.
First-quarter earnings reports are flooding the wires this week and both the Nasdaq and S&P 500 have attained all-time highs. The space has been hurt by political rhetoric as the 2020 election cycle starts to get in full swing. Let's consider a few biotech names and start on a high note.
The Leawood pet drug company, founded in 2010, was the metro area's fastest-growing company last year.
Shares of Aratana Therapeutics shot up 39% in premarket trade on Friday after Elanco Animal Health announced it would be acquiring the pet therapeutics company in a deal worth up to $245 million. For each share of Aratana, shareholders will receive 0.1481 shares of Elanco stock and one contingent value right of 25 cents that will be paid upon meeting certain sales goals. The deal is expected to close by mid-year, the companies said. Shares of Elanco fell 0.7% in premarket trade but are up 2.7% in the year to date, while the S&P 500 is up 16.7%.
Is Elanco Animal Health Incorporated (NYSE:ELAN) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably but historically their consensus […]
How Major Pharmaceutical Stocks Are Positioned This Month(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts have set Eli Lilly and Company’s (LLY) 12-month consensus target price at $122, 2.59% lower than
Why Eli Lilly Stock Fell YesterdayStock price movements Yesterday, Eli Lilly (LLY) closed at $123.50, 2.53% lower than its previous closing price, 65.75% higher than its 52-week low of $74.51, and 5.37% below its 52-week high of $130.51. The
Elanco completed its initial public offering in September 2018, at which point Eli Lilly was a majority shareholder with an 80.2-percent stake. Shareholders could exchange all, some or none of their Eli Lilly stock. The ultimate exchange ratio was settled at 4.5121 shares of Elanco common stock for each share of Eli Lilly common stock.
Elanco or Zoetis: Which Is a Better Animal Health Pick in February?(Continued from Prior Part)Revenue guidance for fiscal 2019In its fourth-quarter earnings investor presentation, Elanco Animal Health (ELAN) confirmed its fiscal 2019 guidance
Elanco or Zoetis: Which Is a Better Animal Health Pick in February?Stock price movementsOn February 19, Elanco Animal Health (ELAN) closed at $29.16, 1.49% lower than its previous closing price, 4.14% higher than its 52-week low of $28.00, and
Warning! GuruFocus has detected 2 Warning Sign with ELAN. For the last quarter Elanco Animal Health Inc reported a revenue of $799.3 million, compared with the revenue of $697.1 million during the same period a year ago. The Elanco Animal Health Inc had a decent operating margin of 10.23%, compared with the operating margin of 4.93% a year before.
Investors need to pay close attention to Elanco Health (ELAN) stock based on the movements in the options market lately.